Éric Lévesque
Chercheur universitaire clinicien
Axe Endocrinologie et néphrologie
Métastases et progression du cancer
Tumeurs cancéreuses solides
Urologie
Oncologie clinique
Pharmacogénomique
Publications
View all-
article Feng T, Xie N, Gao L, Jia Q, Kung S, Morova T, Li Y, Wang L, Fazli L, Lacombe L, Guillemette C, Lévesque E, Lack NA, Qi J, Han B, Dong X
Non-canonical functions of UGT2B17 promote castrate-resistant prostate cancer progression
J Clin Invest 2025.
-
article Lapointe-Belleau A, Rouleau M, Villeneuve L, Descarreaux J, Caron P, Beaudoin C, Uchil A, Simonyan D, Dahmani C, Joly-Beauparlant C, Gélinas V, Droit A, Marcoux N, Castonguay V, Lacombe L, Lévesque É and Guillemette C
Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer
BMC Cancer 25 (1), 2025.
-
article Uchil A, Lacombe L, Hovington H, Brisson H, Simonyan D, Caron P, Ouellet V, Latour M, Aprikian A, Bergeron A, Chevalier S, McKercher G, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Carmel M, Hamilou Z, Trudel D, van der Kwast T, Mes-Masson AM, Dong X, Saad F, Guillemette C, Lévesque E
Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Netwo…
Eur Urol Oncol 2025.
Projects
- Découverte de biomarqueurs pronostiques et prédictifs en cancer de la prostate., from 2024-05-22 to 2027-05-22
- UGT2B28 IS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN PROSTATE CANCER, from 2023-09-01 to 2025-08-31